Ken Frazier, AP Images
It's not just about Keytruda, Merck insists, as it carves out assets worth $6.5B into new company
As sales of Merck’s flagship therapy Keytruda grow from strength to strength — the New Jersey drugmaker is spinning off its women’s health, legacy brands, and biosimilar drugs into a new company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.